Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor- |
RCV000239667 | SCV000298030 | likely pathogenic | Erythroleukemia, familial, susceptibility to | criteria provided, single submitter | research | ||
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003323478 | SCV004029356 | uncertain significance | not specified | 2023-07-24 | criteria provided, single submitter | clinical testing | Variant summary: ERBB3 c.4009G>A (p.Ala1337Thr) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00011 in 247050 control chromosomes (gnomAD). To our knowledge, c.4009G>A has not been reported in the literature in individuals affected with Lethal congenital contracture syndrome 2. At least one publication reports experimental evidence evaluating an impact on protein function, however, does not allow convincing conclusions about the variant effect (example: Braunstein_2016). The following publication has been ascertained in the context of this evaluation (PMID: 27416908). Based on the evidence outlined above, the variant was classified as uncertain significance. |
OMIM | RCV000239667 | SCV000852036 | risk factor | Erythroleukemia, familial, susceptibility to | 2024-10-16 | no assertion criteria provided | literature only |